Introduction {#sec1_1}
============

Bullous pemphigoid (BP) is a blistering autoimmune disease mainly observed in elderly patients. IgG1 and IgG4 autoantibodies against the BP180/BP230 antigen, part of hemidesmosomes, lead to the formation of subepidermal blisters, which can form large bullae \[[@B1]\].

Several triggers have been discussed, such as drugs, vaccinations, radiotherapy, UV radiation, burns, surgical procedures, and various infections \[[@B1]\]. Only few cases document the onset of BP after initiation of TNF inhibitor treatment with adalimumab. We present a patient who received adalimumab therapy for ulcerative colitis and consecutively developed BP.

Case Report {#sec1_2}
===========

The patient (81 years old, white, 1.85 m, 105 kg) said that ulcerative colitis was diagnosed 40 years ago. After moving houses 5 years ago, the gastrointestinal symptoms aggravated. Therefore, a therapy with adalimumab was initiated after an application with azathioprine had to be quit due to elevated liver enzymes.

Only a few days after receiving the second out of 6 injections of the second cycle, the patient noticed a first blister located on his right arm. In the following days, more blisters -- on both arms, on both thighs, on the abdomen, and on the back -- appeared. Simultaneously, a slight pruritus emerged. Initially, therapy was started with topical betamethasone.

By the time the patient presented to our clinic, numerous, coalescing, hemorrhagic lesions as well as scattered tense blisters on the extremities and the abdomen were seen. Figure [1](#F1){ref-type="fig"} shows the clinical appearance of the patient shortly after admission to our clinic. He had been taking irbesartan, bisoprolol, torasemide, atrovastatine, acetylsalicylic acid, mirtazapine, mesalazine, kaliumchloride, and levothyroxine for 6 years. The use of herbal medication or supplements as well as kidney dysfunction, dehydration, lately performed surgical procedures, strenuous physical activities, or vaccinations were denied by the patient. There was no association between the blisters\' appearance and new drugs, other than adalimumab. A skin biopsy performed shortly after admission to our hospital showed a subepidermal blister with fibrin deposits as well as eosinophils and neutrophils within the blister. Numerous granulocytes and eosinophils were also found in the upper corium (Fig. [1](#F1){ref-type="fig"}).

In addition to the already mentioned skin findings, small ulcers located at both lateral ankles were observed.

The laboratory findings showed an increased BP180 of 1: 2,560 (reference range, \< 1: 10). Tests for HHV8, hepatitis B, hepatitis C, *Helicobacter pylori*, and *Toxoplasma gondii* were negative. We initiated a therapy with 80 mg prednisolone (1 mg/kg), which we increased up to 100 mg after 3 days as new blisters showed up. The ongoing formation of blisters during the first 7 days of treatment led us to adjust the immune-suppressive therapy up to 120 mg prednisolone for 2 days. From day 10 on, the therapy with prednisolone was tapered. Azathioprine was not an option because of hepatic parenchyma damage (elevated liver enzymes after a therapy with azathioprine 6 months ago). Nevertheless, we started with methotrexate 15 mg s.c. per week on the 10th day. Although we did not presume torasemide to be the trigger for BP, we switched this medication to hydrochlorothiazide (HCT) 12.5 mg on day 7.

Discussion {#sec1_3}
==========

To date, there are many reported cases of drug-induced BP. Furosemide has been associated with the occurrence of BP before \[[@B2]\]. Although the dose of torasemide had been raised some weeks before the first blisters appeared, we came to the conclusion that this substance was not the trigger of the patient\'s BP. In fact, he had been treated with torasemide before -- for the first time in 2011. An increased dose of torasemide is very unlikely to be the cause of BP in this case.

Recently Wessman et al. \[[@B3]\] described a 49-year-old white man with BP after undergoing adalimumab treatment. The first time BP was mentioned as an adverse reaction to adalimumab was by Stausbøl-Grøn et al. \[[@B4]\] in 2009.

TNF-α inhibitors are known to increase autoantibody production \[[@B5]\]. The incidence of systemic lupus erythematosus and the exacerbations of multiple sclerosis appear to be more frequent in a collective undergoing TNF-α inhibitor medication.

These findings have been explained with 2 pathomechanisms: an amount of antigens from apoptotic cells either leads to the formation of autoantibodies or there is an unbalanced cytotoxic T-cell response. Due to this disbalance, autoreactive B cells are no longer efficiently suppressed \[[@B6], [@B7]\].

These explanations are speculative, but could be taken into account for the initiation of BP under adalimumab medication. Nevertheless, there is no final answer and further work is needed in order to understand this phenomenon and to explore the pathophysiology of the whole process.

The titers of antinuclear and anti-dsDNA are checked routinely during adalimumab application in order to screen for autoimmune reactions. In line with that, Wessman et al. \[[@B3]\] suggest to establish an additional anti-BP180 measurement under therapy with TNF-α inhibitors. This could promote an early detection and in consequence decline the outbreak of BP.
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